Keywords: epix, ms-325, clears, second, ph, iii, trial

EPIX' MS-325 clears second Ph III trial in MRA

Article | 17 March 2003

Print This

Data from a second Phase III trial of EPIX Medical's blood pool contrastagent, MS-325, have confirmed its utility for detecting ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in